SRRK at a glance
Scholar Rock Holding Corp (SRRK, SEC CIK 1727196) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 15, 2026 and Form 4 insider filings as recently as September 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Scholar Rock Holding Corp (SRRK) reported revenue of $0 and a net loss of $377.9 million. Diluted EPS was -$3.29.
- As of June 30, 2026, 33 institutional investment managers tracked by SignalX reported holding Scholar Rock Holding Corp (SRRK) shares worth $2.9 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Peng Katie on July 1, 2026 of 21 shares at $54.96 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 33 funds
- $2.9B · +4 vs prior quarter
- Latest 8-K
- Sep 15, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: Biopharmaceutical company developing selective monoclonal antibodies targeting latent growth factors for rare neuromuscular diseases
- New products emphasized: Apitegromab subcutaneous formulation and SRK-439 anti-latent myostatin antibody, both in clinical development in 2026
- Strategic shift: Transitioning to global commercial-stage biotech; appointed new CEO and expanded U.S./European commercial teams (~50 employees)
- Notable metric: Submitted BLA for apitegromab in SMA in Jan 2025; received FDA Priority Review and EMA MAA acceptance in March 2025
- Unique fact: Apitegromab is first myostatin inhibitor with positive Phase 3 SAPPHIRE study outcome and plans to target additional indications including infants under 2 years and FSHD
Risk Factors
- FDA CRL September 2025 for apitegromab due to third-party fill-finish facility GMP deficiencies, delaying BLA resubmission and potential commercialization
- Geopolitical risk: EMA MAA review may be delayed or rejected due to mutual recognition of FDA’s OAI classification of the manufacturing site
- Supply chain risk: reliance on limited third-party manufacturers for materials, with potential interruptions or quality issues impacting clinical/commercial supplies
- Competitive risk: dependence on continued availability of approved SMN-targeted treatments (e.g., nusinersen, risdiplam) for apitegromab trials; limited access could halt trials
- Financial risk: ongoing net losses and urgent need for additional capital to fund development and commercialization of apitegromab, SRK-181, SRK-439
Management Discussion & Analysis
- Net loss $377.9M in 2025 vs $246.3M in 2024, operating expenses up 52.6% to $384.6M from $252.1M
- R&D expense $208.4M (+12.9%), G&A expense $176.2M (+161.0%), driven by commercial launch prep for apitegromab
- Apitegromab R&D costs rose 14.7% to $89.8M; SRK-181 decreased 75.8%, SRK-439 decreased 22.9%
- Cash, cash equivalents, and securities $367.6M at 2025 YE, down $69.7M YoY; net cash used in operations $300.0M
- Raised $91.7M from ATM stock sales, $50M from debt facility, $63.8M from warrant exercises in 2025
- FDA CRL for apitegromab due to third-party fill-finish issues; resubmission pending resolution, Phase 2 trial in FSHD planned mid-2026
- Management expects ongoing substantial expenses for R&D, commercialization, and infrastructure build ahead of potential apitegromab launch
AI summary of the SRRK 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- FDA CRL triggered by third-party fill-finish facility inspection observations; BLA resubmitted March 2026 with September 30, 2026 PDUFA date
- EMA approval risk from FDA OAI classification and GMP noncompliance, potentially causing delayed review or negative CHMP opinion
- FDA staffing and resource reductions in 2025 threaten timely review of the accepted BLA resubmission
- Commercialization risk from limited sales, distribution, marketing, and market-access capabilities ahead of potential U.S. and European launch
- Capital requirement risk from continuing net losses and need for additional funding to complete development and commercialization
AI summary of the SRRK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 7.01: Regulation FD Disclosure
- No substantive Regulation FD disclosure or investor-actionable information in provided text
Item 7.01: Regulation FD Disclosure
- Exhibits 99.1 and 99.2 furnished under Regulation FD, not treated as filed under Exchange Act Section 18
- Limited liability protections for the company regarding exhibit contents
Item 8.01: Other Events
- FDA approval of ISEMBYLD™ (apitegromab-mstn) for spinal muscular atrophy
- Label covers adults and children aged 2 years and older receiving survival SMN2-targeted treatment
Item EX-99.1: Item EX-99.1
- FDA approval transforms Scholar Rock into a commercial-stage company with ISEMBYLD for SMA patients ≥2 years receiving SMN2-targeted therapy
- Phase 3 SAPPHIRE showed 2.2-point HFMSE improvement versus placebo at 10 mg/kg, with nominal p=0.0121
Item 2.02: Results of Operations and Financial Condition
- Quarterly results released for period ended June 30, 2026
- Financial and operating details furnished in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- Q2 net loss $109.9M, or $0.84 per share, broadly stable year over year despite 16% higher weighted-average shares
- Cash, equivalents and marketable securities $492.1M, including $62.8M ATM proceeds, supporting launch preparation and ongoing trials
AI summaries of SRRK 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SRRK
Don't miss the next SRRK filing
- Alerts as it files. A push when SRRK files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SRRK, by share count.
- Ask anything. An AI agent that reads every SRRK filing and answers with sources.
SRRK alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Woods Keith | G | Sep 24, 2026 | 48,034 | - |
| Hallal David | G | Sep 21, 2026 | 36,652 | - |
| Peng Katie | Sell | Jul 1, 2026 | 21 | $54.96 |
| Reed Joshua | Sell | Jul 1, 2026 | 2,105 | $53.50 |
| Peng Katie | Sell | Jul 1, 2026 | 2,988 | $53.56 |
| Peng Katie | Sell | Jul 1, 2026 | 2,437 | $54.25 |
| Gilman Michael | Sell | Jul 1, 2026 | 1,346 | $53.54 |
| Burow Kristina | Sell | Jul 1, 2026 | 2,105 | $53.49 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | - | $0 |
| Operating Income | -$171.3M | -$252.1M | -$384.6M |
| Net Income | -$165.8M | -$246.3M | -$377.9M |
| Balance Sheet | |||
| Total Assets | - | $474.9M | $404.3M |
| Equity | $225.2M | $368.6M | $245.5M |
| ROE | -73.6% | -66.8% | -154.0% |
| Per Share | |||
| EPS | $-1.99 | $-2.47 | $-3.29 |
| Cash Flow | |||
| Operating CF | - | -$200.9M | -$300.0M |
| CapEx | $71K | $98K | $602K |
Source: XBRL data in Scholar Rock Holding Corp (SRRK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SRRK share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 33 | $2.91B |
| Q1 2026 | 29 | $2.24B |
| Q4 2025 | 26 | $1.93B |
| Q3 2025 | 27 | $1.59B |
| Q2 2025 | 29 | $1.54B |
| Q1 2025 | 25 | $898.2M |
| Q4 2024 | 22 | $1.11B |
| Q3 2024 | 16 | $52.5M |
- BlackRock+2.02M (+27%)
- Morgan Stanley+1.32M (+603%)
- Vanguard Capital Management LLC+876.5K (+23%)
- Franklin Resources+851.8K (+3169%)
- FMR LLC (Fidelity)+752.1K (+4%)
- Citadel Advisors LLC−568.9K (-63%)
- Bank of America Corp−364.4K (-27%)
- Two Sigma Investments−169.1K (-95%)
- Invesco Ltd−25.4K (-21%)
- Raymond James Financial−12.9K (-5%)
- Renaissance Technologies LLC+91.5K
- Millennium Management+18.1K
- Blackstone Group+9.3K
- Allstate+6.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 207 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SRRK filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 23, 2026 | - | - | - |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 8-K | Sep 14, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Apr 24, 2026 | - | - | - |
| 4 | Apr 20, 2026 | - | - | - |
| 4 | Apr 20, 2026 | - | - | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
SRRK SEC filings: frequently asked questions
Which institutions hold SRRK stock?
As of June 30, 2026, the largest Scholar Rock Holding Corp (SRRK) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($989.7 million), BlackRock ($522.2 million), T. Rowe Price Group ($373.7 million), Vanguard Capital Management LLC ($262.2 million), State Street Corp ($260.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SRRK's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Scholar Rock Holding Corp (SRRK) reported revenue of $0 and a net loss of $377.9 million. Diluted EPS was -$3.29. The figures come from the XBRL data in the 10-K.
What are the main risks in SRRK's latest 10-K?
In the 10-K filed March 3, 2026, Scholar Rock Holding Corp (SRRK) flagged: FDA CRL September 2025 for apitegromab due to third-party fill-finish facility GMP deficiencies, delaying BLA resubmission and potential commercialization. Geopolitical risk: EMA MAA review may be delayed or rejected due to mutual recognition of FDA’s OAI classification of the manufacturing site. (AI summary of the Risk Factors section.)
What did SRRK report in its latest 8-K?
Scholar Rock Holding Corp (SRRK) filed an 8-K on September 15, 2026 reporting Item 7.01 (Regulation FD Disclosure). No substantive Regulation FD disclosure or investor-actionable information in provided text.
What are the latest SRRK SEC filings?
Scholar Rock Holding Corp (SRRK) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 15, 2026 and a Form 4 insider filing on September 25, 2026.
What is SRRK's SEC CIK number?
Scholar Rock Holding Corp (SRRK)'s SEC Central Index Key (CIK) is 1727196. EDGAR lists every SRRK filing under that number.
Ask anything about SRRK
The research agent reads SRRK's filings, financials, insider trades and 13F holders, then answers with sources.